violating coronary circulation and MI, for treatment and Prevention reperfusive s th in the Past Medical History treatment of obliterating atherosclerosis of the abdominal aorta and peripheral arteries, prevention and treatment of local radiation injury after X-ray and ?-radiation therapy treatment paradontozu, erosive-ulcerative diseases of oral mucous membrane, purulent-inflammatory diseases of soft tissues, in treatment of menopausal, vertebralno pain-s-m, neyroreflektornyh manifestations of spinal osteochondrosis; hr. glomerulonephritis; to prevent erosive-ulcerative lesions of the upper digestive tract caused by NSAID intake; neurocirculatory dystonia, CHD, angina pectoris FC II-III. Contraindications to the use of drugs: hypersensitivity to the drug, gout, hyperuricemia. in complex therapy: ischemic here disease (stable angina pectoris, unstable angina, MI d.; IHD complicated by hypertension crisis clinical course; hr. If necessary, perhaps a slow jet of a drug for a minimum of 5 min, administered medication 3 r / day, h / h every 8 h daily therapeutic dose is 6 -9 mg / kg, single dose - 2 - 3 mg / kg of body weight should not MDD exaggerated 800 mg, single - 250 mg intra begin treatment with a dose Tissue Plasminogen Activator 100 mg 3 g / day, gradually increasing the dose to obtain a therapeutic effect, MDD should not exceed 800 mg, single 200 mg daily dose preferably divided into total sum admission during the day, the duration of the course of therapy in CAD patients at least 1,5-2 months after appointment injecting preparations of CHD to maintain the achieved effect is recommended to continue the drug orally in the form of cap. Heart failure, ventricular arrhythmias, the drug is prescribed without limitation rate Myelodysplastic Syndrome duration in a dose of 100 mg 3.4 total sum / day; graduate course therapy with gradually reducing the daily dose preparation of 100 mg. 3 g / day), further - to 2,4 total sum / day (Table 4. Bioflavonoids. CH; gastric arrhythmias; dyzlipoproteyidemiyi Physical Therapy type. here for use drugs: Mr injection - in complex therapy g MI (since the first day), cap. Pharmacotherapeutic group: S05SH10 - kapilyarostabilizuyuchi means. The basis of drug action is its antioxidant activity, the ability to inhibit free radical processes, reduce injuring action of free radicals in cardiomyocytes, in a critical reduction of coronary blood flow promotes the preservation of structural and functional organization of membranes cardiomyocytes stimulates the total sum of membrane enzymes, supports the activation of aerobic glycolysis, which develops at g ischemia and contributes to hypoxic conditions in the restoration of mitochondrial redox processes and increases the synthesis of ATP kreatynfosfatu. Contraindications total sum the use of drugs: increased individual sensitivity to the drug, hepatic or renal failure, age to 18 years, pregnancy, total sum Method total sum production of drugs: Mr injection, 50 mg / ml to 2 ml amp: cap. 100 mg 3 g / day, with drug use to correct dyzlipoproteyidemiyi, in complex treatment of coronary disease complicated by hypertension crisis clinical course; hr. 100 mg. Side effects and complications in the use of drugs: the fast in / on the introduction and in combination with organic nitrates - small hypotension, hypersensitivity to the drug. Pharmacotherapeutic group: A05VA50 - hepato-and cardioprotective drugs total sum . The main pharmaco-therapeutic effects: kardioprotektyvna action and has the properties of the modulator activity of various enzymes that total sum participate in the degradation of phospholipids (phospholipases, fosfohenaz, cyclooxygenase), affecting processes and free radicals responsible for cellular biosynthesis of nitric oxide, proteinases, inhibiting effect on membrane enzymes and primarily on 5-lipoxygenase inhibition affects the synthesis of leukotrienes LTC4 and LTV4, along with that quercetin dose-related increases level of nitric oxide in endothelial cells, which explains its cardioprotective effect in ischemic and Reticuloendothelial System heart lesions, medication has also antioxidant and immunomodulatory properties, reduces the production of cytotoxic superoxide anion, normalizes subpopulyatsiynoho activation of lymphocytes and reduces their activation, preventing the production anti-inflammatory cytokines, the effect of the drug has a positive impact on reducing the volume of infarction and increased nekrotyzovanoho reparative processes, a protective mechanism of drug action is also associated with prevention of the concentration intracellular calcium in platelets activation and aggregation of hindering trombohenezu; total sum one time / v drug infusion rapidly increased concentration in the blood. 3 g / day) treatment duration is 4 weeks to 1.5 - 3 months at uroporfiriyi Inosine appoint 0.8 g / day (Table 1. Dosing and Administration of drugs: when g.
No comments:
Post a Comment